TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	178.69	133.36	120.03	161.41	34.79
Short-Term Investments	111.42	58.69	-	-	-
Cash & Short-Term Investments	290.11	192.04	120.03	161.41	34.79
Cash Growth	51.06%	60.00%	-25.64%	363.93%	-16.70%
Prepaid Expenses	2.61	2.19	4.1	4.25	1.65
Total Current Assets	292.72	194.24	124.13	165.65	36.45
Property, Plant & Equipment	71.6	71.23	69.2	17.26	12.53
Other Long-Term Assets	6.8	6.68	5.76	5.2	0.76
Total Assets	371.12	272.15	199.09	188.11	49.74
Accounts Payable	4.28	2.37	2.91	1.77	2.91
Accrued Expenses	15.33	10.29	6.41	5.51	2.36
Current Portion of Long-Term Debt	-	3.35	-	-	-
Current Portion of Leases	4.57	3.25	3.68	1.65	1.42
Current Unearned Revenue	11.7	10.14	3.87	11.41	10.63
Other Current Liabilities	0.08	0.43	0.43	1.01	0.13
Total Current Liabilities	35.96	29.82	17.31	21.34	17.45
Long-Term Debt	32.07	26.7	29.29	-	-
Long-Term Leases	60.74	59.14	53.01	4.39	6.02
Long-Term Unearned Revenue	1.25	5.62	-	1.5	8.82
Other Long-Term Liabilities	0.14	-	0.05	0.1	0.24
Total Liabilities	130.15	121.28	99.66	27.33	32.52
Common Stock	0.01	0.01	0	0	0
Additional Paid-In Capital	616.01	398.46	257.81	252.93	1.07
Retained Earnings	-375.1	-247.6	-158.38	-92.16	-43.53
Comprehensive Income & Other	0.05	-	-	-	-
Total Common Equity	240.97	150.87	99.43	160.78	-42.46
Shareholders' Equity	240.97	150.87	99.43	160.78	17.22
Total Liabilities & Equity	371.12	272.15	199.09	188.11	49.74
Total Debt	97.38	92.43	85.98	6.04	7.43
Net Cash (Debt)	192.73	99.61	34.04	155.36	27.36
Net Cash Growth	93.48%	192.60%	-78.09%	467.91%	-25.82%
Net Cash Per Share	3.41	2.08	1.42	13.32	29.87
Filing Date Shares Outstanding	56.59	47.88	24.23	23.86	1.14
Total Common Shares Outstanding	56.59	47.83	24.23	23.91	1.14
Working Capital	256.77	164.42	106.82	144.31	19
Book Value Per Share	4.26	3.15	4.10	6.72	-37.38
Tangible Book Value	240.97	150.87	99.43	160.78	-42.46
Tangible Book Value Per Share	4.26	3.15	4.10	6.72	-37.38
Machinery	22.59	18.63	16.87	12.15	6.14
Construction In Progress	0.1	0.55	0.01	1.26	0.78
Leasehold Improvements	3.26	3.16	3.45	3.43	0.49

Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q